In March 2010, Orexigen(R) Therapeutics submitted a new drug application (NDA) 
for approval of naltrexone sustained release (SR)/bupropion SR (Contrave(R)) for 
the treatment of obesity in the US. The tablet contains naltrexone SR 32 mg and 
bupropion SR 360 mg. The drug has been tested in four randomized, double-blind, 
placebo-controlled, phase III trials and the co-primary endpoints were met in 
each case. This review discusses the key development milestones and clinical 
trial program to date.